Breast Cancer

Breast Health

COVID-19

Cervical Health 

Contraception

Curbside Consults

Dermatology

Drug Pipeline News

Endometriosis

Genetic Testing

Gynecologic Oncology

Gynecology

Fetal Imaging

Abnormal Obstetrical Ultrasound

Ultrasound

Women's Imaging

Breast Imaging

Women's Ultrasound

Imaging

Infertility

LARC

Labor and Delivery

Legally Speaking

Life Transitions

Malpractice

Menopause

Mental Health

Noninvasive Prenatal Testing

Obstetrics

Opinion

Osteoporosis

Pediatrics

Practice Management

Pregnancy and Birth

Procedures

Sexual Dysfunction

Sexual Health

Sexually Transmitted Diseases

Surgery

Technology

Urology

Uterine Fibroids

Vulvovaginal Disease

Well Woman

About

News

Media

Podcasts

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Videos

Conferences

Conference Coverage

Conference Listing

Publications

Contemporary OB/GYN® Journal

Digital Supplements

CME/CE

Resources

Physician Fact Sheets

Interactive Tools

Supplements and Featured Publications

Subscribe

Print Subscription

eNewsletter

Editorial Board

Partnerships

Articles

Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women. 

Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive

A study reveals how personalized digital health tools, such as a Digital Personal Health Librarian, leveraging electronic health records, social data, and advanced technologies, can not only enhance wellness care and preventive health but also significantly improve the uptake of interventions like HPV vaccination.

Digital personal health coaching platform for promoting human papillomavirus infection vaccinations and cancer prevention: Knowledge graph-based recommendation system

Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.

Exploring menstrual health: Insights from the Avon longitudinal study

Discoveries from a comprehensive study reveal specific plasma biomarkers that may serve as indicators of neurological well-being in individuals living with HIV, shedding light on potential links to Alzheimer's disease and emphasizing the importance of early detection for improved outcomes.

How plasma biomarkers illuminate brain health in women with HIV 

Advertise

Contact Us

Job Board

Terms of Use

Privacy Policy

Do Not Sell My Personal Information

Contemporary OB/GYN

Twitter

Facebook

LinkedIn

RSS Feed

Spotlight

CMV: In the Know

NPWH

Supplement: Closing the Gap in Cervical Cancer Screening

Vaginismus: Managing a Misunderstood and Underdiagnosed Condition

Why vNOTES Make Sense for My Patients

1rem

Authors

Jessica Shields, DO, is the associate program director of the Fellowship in Minimally Invasive Gynecologic Surgery and an assistant professor at the University of Texas Southwestern Medical Center in Dallas.

Primary dysmenorrhea is a prevalent, underdiagnosed, but treatable condition. 

Diagnosis and Management of Primary Dysmenorrhea